



(PW)

PATENT  
Attorney Docket No. 056291-5258

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: **Rodney Brian Hargreaves et al.** ) Confirmation No.: **7098**  
Application No.: **10/534,651** ) Group Art Unit: **1625**  
Filed: **May 12, 2005** ) Examiner: **Seaman, D Margaret M**  
For: **Quinoline Derivatives as Glucokinase** )  
**Ligands** ) **Date: June 30, 2006**

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Window, Mail Stop Amendment  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**UNDER 37 C.F.R. § 1.97(c)**

**Citation of Technically Related U.S. Patent Applications**

The Examiner's attention is directed to the following technically related U.S. patents or applications of Applicant's assignee:

Inventor	U.S. Serial No. Filing Date	U.S. Pub. /Patent No. Publication Date	PCT Publ. No. Date
Barry Raymond Hayter et al.	10/482,264 December 23, 2005	US 20050054715 March 10, 2005	WO 03/000262 January 3, 2003
Barry Raymond Hayter et al.	10/482,572 December 22, 2003	US 20040214868 October 28, 2004	WO 03/000267 January 3, 2003
Scott Boyd et al.	10/486,496 February 11, 2004	US 20050080106 April 14, 2005	WO 03/015774 February 27, 2003
Darren Mckerrecher et al.	10/534,650 May 12, 2005	US 20060058353 March 16, 2006	WO 2004/046139 June 3, 2004
Peter William Rodney Caulkett et al.	10/578,021 April 28, 2006		WO 2005/044801 May 19, 2005
Craig Johnstone et al.	10/579,337 May 15, 2006		WO 2005/054200 June 16, 2005
Craig Johnstone et al.	10/579,552 May 16, 2006		WO 2005/054233 June 16, 2005

Where a published US application is not available, the undersigned understands that the text of each related application is essentially the same as the above listed published PCT Application.

Consideration of each listed application is earnestly solicited. Copies of the listed published PCT applications have been previously submitted to the U.S. Patent and Trademark Office.

Pursuant to 37 C.F.R. 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449 form. This Supplemental Information Disclosure Statement (IDS) is being filed after the events recited in § 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final Office Action or a Notice of Allowance. The Commissioner is hereby authorized to charge \$180.00, as specified by § 1.17(p), to Deposit Account No. 50-0310 for this Supplemental Information Disclosure Statement under the provisions of 37 C.F.R. § 1.97(c).

With the exception of the U.S. Patents, copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that the listed documents constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


If there are any additional fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 50-0310. If a fee is required for an extension of time under 37 C.F.R.

§1.136 not accounted for above, such an extension is requested and the fee should also be charged to our  
Deposit Account.

Date: June 30, 2006


By:

Morgan Lewis & Bockius LLP  
Customer No. 09629  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel. No.: 202-739-3000

  
\_\_\_\_\_  
Gregory T. Lowen  
Registration No. 46,882  
Tel. No.: (202) 739-5320  
Fax No.: (202) 739-3001

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

PTO Form 1449  
June 30, 2006Attorney Docket No.  
056291-5258Application No.  
10/534,651Applicants: Rodney Brian Hargreaves *et al.*

Page 1 of 2

Filing Date: May 12, 2005

Group Art Unit: 1625

**U.S. PATENT DOCUMENTS**

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
1.	US 4,146,631	March 27, 1979	Ford, et al.	514	381	November 3, 1977

**FOREIGN PATENT DOCUMENTS**

	Document No.	Date	Country	Class	Sub-Class	Translation
2.	EP 1600442	November 30, 2005	Europe			
3.	JP 08 173525	July 9, 1996	Japan			Abstract
4.	JP 08 301760	November 19, 1996	Japan			Yes
5.	WO 01/19788	March 22, 2001	WIPO			
6.	WO 2004/076420	September 10, 2004	WIPO			Yes
7.	WO 2005/063738	July 14, 2005	WIPO			Yes
8.	WO 2005/066145	July 21, 2005	WIPO			
9.	WO 2005/080359	September 1, 2005	WIPO			
10.	WO 2005/080360	September 1, 2005	WIPO			
11.	WO 2005/090332	September 29, 2005	WIPO			Yes
12.	WO 2005/095417	October 13, 2005	WIPO			
13.	WO 2005/095418	October 13, 2005	WIPO			
14.	WO 2005/103021	November 3, 2005	WIPO			
15.	WO 2005/121110	December 22, 2005	WIPO			
16.	WO 2005/123132	December 29, 2005	WIPO			
17.	WO 2006/016174	February 16, 2006	WIPO			
18.	WO 2006/016178	February 16, 2006	WIPO			
19.	WO 2006/016194	February 16, 2006	WIPO			
20.	WO 2006/040527	April 20, 2006	WIPO			
21.	WO 2006/040528	April 20, 2006	WIPO			
22.	WO 2006/040529	April 20, 2006	WIPO			

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

23.	Anderson et al "Pyridopyrimidines. 6. Nucleophilic substitutions in the Pyrido[2,3-d]pyrimidine series" J. Org. Chem. 42(6):993-996 (1977)
24.	Ando et al. "Fluoride salts on alumina as reagents for alkylation of phenols and alcohols" Bull. Chem. Soc. Jpn., 55:2504-2507 (1982)
25.	Coghlan "Small molecule Glucokinase Activators (GKAs) as novel anti-diabetic agents" Society for Medicines Research Seminar (June 2004)
26.	Coghlan "Small molecule Glucokinase Activators (GKAs) as novel anti-diabetic agents" CIDEM seminar (May 2005)
27.	Gill et al. "Stimulation of insulin release by a small molecule glucokinase activator" EASD Islet Study Group Abstract (November 2005)
28.	Kunishima et al. "4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium chloride: An efficient condensing agent leading to the formation of amides and esters" Tetrahedron 55:13159-13170 (1999)
29.	Leighton et al. "Small molecule glucokinase activators as novel anti-diabetic agents" Biochem Soc Trans. 33(Pt 2):371-374 (April 2005)
30.	McKerrecher "Design and synthesis of novel glucokinase activators" 13th RSC-SCI Medicinal Chemistry Symposium, Churchill College Cambridge (September 2005)

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

